€19.13
Your prediction
Catalyst Pharmaceutical Partners Inc Stock
Pros and Cons of Catalyst Pharmaceutical Partners Inc in the next few years
Pros
Cons
Performance of Catalyst Pharmaceutical Partners Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Catalyst Pharmaceutical Partners Inc | 3.640% | 4.421% | 6.130% | 61.913% | 23.102% | 343.955% | 221.297% |
Evolus Inc | 0.690% | 8.209% | 15.079% | 72.619% | 60.221% | 116.418% | - |
Ardelyx Inc. | 2.780% | -4.516% | -0.739% | 42.819% | -7.093% | 375.221% | 21.783% |
Coherus Bioscien. | 6.000% | -12.403% | -10.907% | -75.986% | -66.546% | -93.220% | -94.772% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Catalyst Pharma (CPRX) appears to be fundamentally improving its financial position, owing to the growth seen in recent financial statements. Observing the company's financials, the trend of increasing revenues, net income, total assets, and shareholder's equity is noticeable. This indicates that Catalyst Pharma has been experiencing a growth phase in its business operations in the market.
*Pros: *
Revenue Growth: The company is experiencing substantial growth in total revenue from 2020 to 2022, which is positive for its financial position. This revenue growth is attributed to the company's ability to successfully market and sell its products, positively reflecting its business operations.
Comments